Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery

Molecular Therapy

Volumn 8, Issue 4, 2003, Pages 530-542

  Niranjan, Ajay ^a   Wolfe, Darren ^a   Tamura, Masakazu ^a   Soares, M Karina ^a   Krisky, David M ^a   Lunsford, L Dade ^a   Li, Songhui ^a   Fellows Mayle, Wendy ^a   DeLuca, Neal A ^a   Cohen, Justus B ^a   Glorioso, Joseph C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Connexin; Gamma knife; Gene therapy; Glioma; Herpesvirus; TNF

Indexed keywords

CONNEXIN 43; GANCICLOVIR; IMMEDIATE EARLY PROTEIN; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER TRANSPLANTATION; CELL DIVISION; CONTROLLED STUDY; FEMALE; GAMMA KNIFE RADIOSURGERY; GENE CONSTRUCT; GENE THERAPY; GENE TRANSFER; GLIOBLASTOMA; GLIOSARCOMA; HERPES SIMPLEX VIRUS 1; IMMEDIATE EARLY GENE; IMMUNOCOMPETENCE; NONHUMAN; NUDE MOUSE; OUTCOMES RESEARCH; RAT; REVIEW; SARCOMA CELL; STATISTICAL ANALYSIS; SUICIDE GENE THERAPY; TUMOR CELL; VIRUS REPLICATION;

ALPHAVIRUS; ANIMALIA; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 10744229567     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00232-6     Document Type: Article

References (56)

1. Prados, M., and Levin, V. (2000). Biology and treatment of malignant glioma. Semin. Oncol. 27: 1-10.
2. Hochberg, F., and Pruitt, A. (1980). Assumptions in the radiotherapy of glioblastoma. Neurology 30: 907-911.
3. Wallner, K., Galicich, J., Krol, G., Arbit, E., and Malin, M. (1980). Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 16: 1405-1409.
4. Sheline, G., Wara, W., and Smith, V. (1980). Therapeutic irradiation and brain injury. Int. J. Radiat. Oncol. Biol. Phys. 6: 1215-1228.
5. Goins, W., Krisky, D., Wolfe, D., Fink, D., and Glorioso, J. (2001). Development of herpes simplex virus replication defective vectors. Methods Mol. Med. 76: 79-102.
6. Krisky, D., et al. (1998). Deletion of multiple immediate early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 5: 1593-1603.
7. Krisky, D., et al. (1998). Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther. 5: 1517-1530.
8. Goss, J. R., et al. (2002). Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes 51: 2227-2232.
9. Moriuchi, S., et al. (1998). Enhanced tumor-cell killing in the presence of ganciclovir by HSV-1 vector-directed co-expression of human TNF-α and HSV thymidine kinase. Cancer Res. 58: 5731-5737.
10. Niranjan, A., et al. (2000). Effective treatment of experimental glioblastoma by HSV vector-mediated TNF-α and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol. Ther. 2: 114-120.
11. Marconi, P., et al. (2000). Connexin43-enhanced suicide gene therapy using herpes-viral vectors. Mol. Ther. 1: 71-81.
12. Moriuchi, S., et al. (2000). HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Ther. 7: 1483-1490.
13. Marconi, P., et al. (1999). Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo. Gene Ther. 6: 904-912.
14. Samaniego, L., Neiderhiser, L., and DeLuca, N. (1998). Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J. Virol. 72: 3307-3320.
15. Chen, X., et al, (2000). Herpes simplex virus type 1 ICP0 protein does not accumulate in the nucleus of primary neurons in culture. J. Virol. 74: 10132-10141.
16. Marconi, P., et al. (1996). Replication-defective HSV vectors for gene transfer in vivo. Proc. Natl. Acad. Sci. USA 93: 11319-11320.
17. Krisky, D., et al. (1997). Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther. 4: 1120-1125.
18. Sauer, B., Whealy, M., Robbins, A., and Enquist, L. (1987). Site-specific insertion of DNA into a pseudorabies virus vector. Proc. Natl. Acad. Sci. USA 84: 3160-3167.
19. Summers, W., Wagner, M., and Summers, W. (1975). Possible peptide chain termination mutants in thymidine kinase gene of a mammalian virus, herpes simplex virus. Proc. Natl. Acad. Sci. USA 72: 4081-4084.
20. Roizman, B., and Sears, A. (1996). Herpes simplex viruses and their replication). Fields Virology (In B. Fields, et al., Eds.), pp. 2231-2295. Lippincott-Raven, Philadelphia.
21. Namba, H., Iwadate, Y., Kawamura, K., Sakiyama, S., and Tagawa, M. (2001). Efficacy of the bystander effect in the herpes simplex virus thymidine kinase-mediated gene therapy is influenced by the expression of connexin43 in the target cells. Cancer Gene Ther. 8: 414-420.
22. Zhang, Y., Morita, I., Ikeda, M., Ma, K., and Murota, S. (2001). Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27. Oncogene 20: 4138-4149.
23. Alexander, E. III., and Loeffler, J. (1998). Radiosurgery for primary malignant brain tumors. Semin. Surg. Oncol. 14: 43-52.
24. Gannett, D., et al. (1995). Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 33: 461-468.
25. Hall, W., et al. (1995). Stereotactic radiosurgery for recurrent malignant gliomas. J. Clin. Oncol. 13: 1642-1648.
26. Kondziolka, D., Flickinger, J., Bissonette, D., Bozik, M., and Lunsford, D. (1997). Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41: 776-785.
27. Kondziolka, D., et al. (1996). Radiosurgery and fractionated radiation therapy: comparison of different techniques in an in vivo rat glioma model. J. Neurosurg. 84: 1033-1038.
28. Loeffler, J., et al. (1992). Radiosurgery as part of the initial management of patients with malignant gliomas. J. Clin. Oncol. 10: 1379-1385.
29. Sarkaria, J., et al. (1995). Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Int. J. Radiat. Oncol. Biol. Phys. 32: 931-944.
30. DeLuca, N., McCarthy, A., and Schaffer, P. (1985). Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J. Virol. 56: 558-570.
31. McCarthy, A., McMahan, L., and Schaffer, P. (1989). Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient. J. Virol. 63: 18-27.
32. Bauer, D., and Tampe, R. (2002). Herpes viral proteins blocking the transporter associated with antigen processing TAP - from genes to function and structure. Curr. Top. Microbiol. Immunol. 269: 87-99.
33. Todo, T., Martuza, R., Rabkin, S., and Johnson, P. (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. USA 98: 6396-6401.
34. Samaniego, L., Wu, N., and DeLuca, N. (1997). The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J. Virol. 71: 4614-4625.
35. Everett, R. (2000). ICP0, a regulator of herpes simplex virus during lytic and latent infection. Bioessays 22: 761-770.
36. Freeman, S., et al. (1993). The "bystander effect:" tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53: 5274-5283.
37. Wu, J. K., et al. (1994). Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 35: 1094-1102.
38. Barba, D., Hardin, J., Ray, J., and Gage, F. H. (1993). Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. 79: 729-735.
39. Culver, K., et al. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552.
40. Ezzeddine, Z. D., et al. (1991). Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 3: 608-614.
41. Ram, Z., Culver, K. W., Walbridge, S., Blaese, R. M., and Oldfield, E. H. (1986). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 46: 5276-5281.
42. Packer, R., et al. (2000). Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg. 92: 249-254.
43. Palu, G., et al. (1999). Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther. 6: 330-337.
44. Trask, T., et al. (2000). Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. 1: 195-203.
45. Moriuchi, S., et al. (2002). Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther. 9: 584-591.
46. Carystinos, G., Bier, A., and Batist, G. (2001). The role of connexin-mediated cell-cell communication in breast cancer metastasis. J. Mammary Gland Biol. Neoplasia 6: 431-440.
47. Huang, R., et al. (2002). Connexin43 suppresses human glioblastoma cell growth by down-regulation of monocyte chemotactic protein 1, as discovered using protein array technology. Cancer Res. 62: 2806-2812.
48. Andrade-Rozental, A., et al. (2000). Cap junctions: the "kiss of death" and the "kiss of life." Brain Res. 32: 305-315.
49. Badgwell, B., et al. (2003). Intra-arterial administration of TNF-alpha followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma. Cancer Immunol. Immunother. 52: 10-16.
50. Niranjan, A., and Lunsford, L. (2000). Radiosurgery: where we were, are, and may be in the third millennium. Neurosurgery 46: 531-543.
51. Gridley, D., et al. (1997). Tumor necrosis factor-alpha enhances antitumor effects of radiation against glioma xenografts. Oncol. Res. 9: 217-227.
52. Leonard, M., Jeffs, R., Gearhart, J., and Coffey, D. (1992). Recombinant human tumor necrosis factor enhances radiosensitivity and improves animal survival in murine neuroblastoma. J. Urol. 148: 743-746.
53. Rasmussen, H., et al. (2002). TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther. 9: 951-957.
54. Sersa, G., Willingham, V., and Milas, L. (1988). Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int. J. Cancer 42: 129-134.
55. Sharma, A., et al. (2001). Clinical protocol: an open-label, phase-1, dose-escalation study of tumor necrosis factor-α (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. Hum. Gene Ther. 12: 1109-1131.
56. Staba, M., Mauceri, H., Kufe, D., Hallahan, D., and Weichselbaum, R. (1998). Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 5: 293-300.